Clinical Study Of The Efficacy Of And Tolerance To Seaprose S In Inflammatory Venous Disease. Controlled Study Versus Serratio-peptidase

Effect Decrease
Trial Design Cohort
Trial Length 1-2 Weeks
Number of Subjects 40
Gender Both Genders
Age Range 30-44, 45-64, 65+
Body Types Average
Notes for this study:
In persons with superficial thrombophlebitis given 30mg serrapeptase (10mg thrice daily) relative to the comparator drug Protease S (Seaprose S; no placebo control in this study) noted that both drugs were able to reduce pain and symptoms of thrombophlebitis, but the symptoms alleviation seen with serrapeptase (65%) was outperformed by protease S (85%).